HopeStageGet research updates
HopeStage
hi@hopestage.com

Built by people with lived experience, between Sydney and Paris.

Back to all studies
Not recruitingEUCTR 2022-002757-26

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesDepression
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
Burgas and 45 more locationsSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Not recruiting
Enrollment listed in the registry
324
Sponsor
HMNC Holding GmbH
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Bulgaria, Estonia, Germany, ...
Age range
Not clearly listed
Official registry ID
EUCTR 2022-002757-26
Official title
Show the full official title

A 14-week, multicentre, double-blind, randomised, placebo-controlled phase II study with an 8-week treatment period to assess the efficacy and tolerability of a fixed dose of BH-200 (250 mg BID) i...

Questions about this study?

The HopeStage team will email you.

Loading the security check...

Recruitment & locations

Not recruiting

Burgas, Bulgaria · Kazanlik, Bulgaria · Pleven, Bulgaria

32 more locations
  • Plovdiv, Bulgaria
  • Ruse, Bulgaria
  • Sofiya, Bulgaria
  • Varna, Bulgaria
  • Vratsa, Bulgaria
  • Tallinn, Estonia
  • Tartu, Estonia
  • Berlin, Germany
  • Bielefeld, Germany
  • Boeblingen, Germany
  • Chemnitz, Germany
  • Jena, Germany
  • Nürnberg, Germany
  • Schwerin, Germany
  • Siegen, Germany
  • Kaunas, Lithuania
  • Ziegzdriu K., Lithuania
  • Belchatow, Poland
  • Gdansk, Poland
  • Katowice, Poland
  • Kielce, Poland
  • Leszno, Poland
  • Lublin, Poland
  • Poznan, Poland
  • Pruszcz Gdanski, Poland
  • Rimavska Sobota, Slovakia
  • Stare Mesto, Slovakia
  • Vranov Nad Toplou, Slovakia
  • Zlate Moravce, Slovakia
  • Alcorcon, Spain
  • Barcelona, Spain
  • Palma, Spain
Checked Official study record (opens in a new tab)
Registry detailsOriginal registry record (opens in a new tab)
Current country statuses
Historical country statuses

A listed location does not confirm current availability.

FAQ

Questions about this study

Who is behind this study?

The study sponsor is HMNC Holding GmbH.

Is this study still recruiting?

The registry lists this study as not recruiting.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me